ATMPs

Oncology

Juggling CMC trade-offs with personalised cancer vaccines

Personalised cancer vaccines offer significant potential to address an unmet medical need in treatment-resistant disease with fewer side effects and less toxicity compared to standard treat

R&D

Modernising EU legislation: The Alliance for Regenerative Me...

Late last month, pharmaphorum met with Stephen Majors, global head of communications for the Alliance for Regenerative Medicine (ARM), to discuss the latest developments in the Advanced The

R&D

Challenges of analytical method validation for ATMPs

Quality control of medicinal products is a fundamental aspect of assuring the quality, efficacy, and safety of the product.

News

Alarm bell rung over EU’s unified HTA plan

The EU’s joint clinical assessment (JCA) initiative has been set up to accelerate patient access to new therapies, but could end up restricting the use of new technologies

R&D